---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000055"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:54:09.555847+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics Q1 net loss $4.8M; cash runway through Q3 2025

## Summary
- Net loss attributable to Serina of $4.8M ($0.49/share) vs $15.0M ($5.38/share) in Q1 2024.
- Cash and cash equivalents $4.3M at March 31, 2025; plus $5M April private placement extends runway through Q3 2025.
- On track to dose first patient in Phase 1b trial of SER-252 for advanced Parkinson's in Q4 2025.
- Secured $15M in equity financing since late 2024, including $10M from JuvVentures and $5M private placement.
- Appointed Karen J. Wilson and Dr. Jay Venkatesan to the Board; POZ-lipid data showed no antibody response in rats.

## SEC filing metadata
- accession: 0001708599-25-000055
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000055/0001708599-25-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000055/ser-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000055
- JSON: https://secwatch.observer/filing/0001708599-25-000055.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.